Literature DB >> 32031055

Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma.

Ning Qu1,2, Xiao Shi1,2, Jing-Jing Zhao2,3, Haixia Guan4, Ting-Ting Zhang1,2, Shi-Shuai Wen1,2, Tian Liao3, Jia-Qian Hu1,2, Wei-Yan Liu5, Yu-Long Wang1,2, Shenglin Huang2,3, Rong-Liang Shi1,2, Yu Wang1,2, Qing-Hai Ji1,2.   

Abstract

Background: Sporadic medullary thyroid carcinoma (MTC) is a relatively uncommon neuroendocrine malignancy and the molecular tumorigenesis of its sporadic type (sMTC) is only partially understood. In this study, we performed a study focusing on the genomic and transcriptomic characterization of sMTC.
Methods: Twenty-nine sMTC patients were included. Whole-exome sequencing (WES) was carried out in 18 patients, including both tumor samples and matched noncancerous tissues. Whole transcriptome sequencing (RNA-Seq) was performed in all 29 tumors. WES, RNA-Seq, and copy number alteration (CNA) data were analyzed. A Cell Counting Kit-8 (CCK-8) assay was used to evaluate cell proliferation.
Results: Among the somatic mutations, RET was the only recurrently cancer-related mutated gene (5/18, 27.8%). In the germline, FAT1 and FAT4, two members of the FAT gene family, were identified as the two most common mutated genes. CNA analysis found that FAT1 and FAT4, both located on chromosome 4q, were also two of the genes most commonly affected by somatic chromosomal deletions (4/18, 22.2%). Using TT and MZ-CRC-1 cell lines, the CCK-8 assay showed that FAT1 and FAT4 knockdown could promote MTC cell proliferation. Based on the gene expression profile, patients were clustered into two molecular subtypes: the mesenchymal-like subtype is characterized by epithelial-mesenchymal transition, while the proliferative-like subtype is associated with enrichment of cell cycle pathways. Most events of structural recurrence (80%) occurred in the proliferative-like subtype.
Conclusion: In addition to RET, these findings demonstrate that FAT1/FAT4 genomic alterations appear to be frequent in sMTC. Two molecular subtypes of sMTC with distinct biological behavior could be identified. However, these results need to be validated by larger samples and more comprehensive experiments in the future, especially for the frequency and function of FAT1/FAT4 germline variants.

Entities:  

Keywords:  FAT1; FAT4; copy number alteration; molecular subtype; multi-omics profiling; sporadic medullary thyroid carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32031055     DOI: 10.1089/thy.2019.0531

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  2 in total

1.  Medullary Thyroid Carcinoma Mutational Spectrum Update and Signaling-Type Inference by Transcriptional Profiles: Literature Meta-Analysis and Study of Tumor Samples.

Authors:  Emanuela Minna; Paola Romeo; Matteo Dugo; Loris De Cecco; Antonella Aiello; Federico Pistore; Andrea Carenzo; Angela Greco; Maria Grazia Borrello
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

2.  A Drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma.

Authors:  Erdem Bangi; Peter Smibert; Andrew V Uzilov; Alexander G Teague; Sindhura Gopinath; Yevgeniy Antipin; Rong Chen; Chana Hecht; Nelson Gruszczynski; Wesley J Yon; Denis Malyshev; Denise Laspina; Isaiah Selkridge; Huan Wang; Jorge Gomez; John Mascarenhas; Aye S Moe; Chun Yee Lau; Patricia Taik; Chetanya Pandya; Max Sung; Sara Kim; Kendra Yum; Robert Sebra; Michael Donovan; Krzysztof Misiukiewicz; Celina Ang; Eric E Schadt; Marshall R Posner; Ross L Cagan
Journal:  iScience       Date:  2021-02-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.